These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 33998604)

  • 1. Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.
    Nyquist MD; Ang LS; Corella A; Coleman IM; Meers MP; Christiani AJ; Pierce C; Janssens DH; Meade HE; Bose A; Brady L; Howard T; De Sarkar N; Frank SB; Dumpit RF; Dalton JT; Corey E; Plymate SR; Haffner MC; Mostaghel EA; Nelson PS
    J Clin Invest; 2021 May; 131(10):. PubMed ID: 33998604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.
    Takayama K; Horie-Inoue K; Suzuki T; Urano T; Ikeda K; Fujimura T; Takahashi S; Homma Y; Ouchi Y; Inoue S
    Mol Endocrinol; 2012 May; 26(5):748-61. PubMed ID: 22456197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.
    Titus MA; Zeithaml B; Kantor B; Li X; Haack K; Moore DT; Wilson EM; Mohler JL; Kafri T
    PLoS One; 2012; 7(1):e30192. PubMed ID: 22272301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling.
    Narayanan R; Ahn S; Cheney MD; Yepuru M; Miller DD; Steiner MS; Dalton JT
    PLoS One; 2014; 9(7):e103202. PubMed ID: 25072326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
    Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
    J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
    Yang Q; Titus MA; Fung KM; Lin HK
    J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
    Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
    Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.
    Evans MJ; Smith-Jones PM; Wongvipat J; Navarro V; Kim S; Bander NH; Larson SM; Sawyers CL
    Proc Natl Acad Sci U S A; 2011 Jun; 108(23):9578-82. PubMed ID: 21606347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
    Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
    Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis.
    Mostaghel EA; Morgan A; Zhang X; Marck BT; Xia J; Hunter-Merrill R; Gulati R; Plymate S; Vessella RL; Corey E; Higano CS; Matsumoto AM; Montgomery RB; Nelson PS
    PLoS One; 2014; 9(10):e111545. PubMed ID: 25356728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone.
    Askew EB; Gampe RT; Stanley TB; Faggart JL; Wilson EM
    J Biol Chem; 2007 Aug; 282(35):25801-16. PubMed ID: 17591767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of selective androgen receptor modulators (SARMs).
    Narayanan R; Coss CC; Dalton JT
    Mol Cell Endocrinol; 2018 Apr; 465():134-142. PubMed ID: 28624515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.
    Schmidt LJ; Duncan K; Yadav N; Regan KM; Verone AR; Lohse CM; Pop EA; Attwood K; Wilding G; Mohler JL; Sebo TJ; Tindall DJ; Heemers HV
    Mol Endocrinol; 2012 May; 26(5):716-35. PubMed ID: 22456196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential proteome expression analysis of androgen-dependent and -independent pathways in LNCaP prostate cancer cells.
    Cha S; Shin DH; Seok JR; Myung JK
    Exp Cell Res; 2017 Oct; 359(1):215-225. PubMed ID: 28736082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesterol Triggers Nuclear Co-Association of Androgen Receptor, p160 Steroid Coactivators, and p300/CBP-Associated Factor Leading to Androgenic Axis Transactivation in Castration-Resistant Prostate Cancer.
    Pimenta R; Camargo JA; Candido P; Ghazarian V; Gonçalves GL; Guimarães VR; Romão P; Chiovatto C; Mioshi CM; Dos Santos GA; Silva IA; Birbrair A; Srougi M; Nahas WC; Leite KR; Viana NI; Reis ST
    Cell Physiol Biochem; 2022 Dec; 56(S4):1-15. PubMed ID: 36458578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The DNA/RNA helicase DHX9 contributes to the transcriptional program of the androgen receptor in prostate cancer.
    Chellini L; Pieraccioli M; Sette C; Paronetto MP
    J Exp Clin Cancer Res; 2022 May; 41(1):178. PubMed ID: 35590370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.
    Mohler JL; Titus MA; Bai S; Kennerley BJ; Lih FB; Tomer KB; Wilson EM
    Cancer Res; 2011 Feb; 71(4):1486-96. PubMed ID: 21303972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivation of androgen-induced regulator ARD1 inhibits androgen receptor acetylation and prostate tumorigenesis.
    Wang Z; Wang Z; Guo J; Li Y; Bavarva JH; Qian C; Brahimi-Horn MC; Tan D; Liu W
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3053-8. PubMed ID: 22315407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Castration-recurrent prostate cancer is not androgen-independent.
    Mohler JL
    Adv Exp Med Biol; 2008; 617():223-34. PubMed ID: 18497046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways.
    Narayanan R; Coss CC; Yepuru M; Kearbey JD; Miller DD; Dalton JT
    Mol Endocrinol; 2008 Nov; 22(11):2448-65. PubMed ID: 18801930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.